concentrations of ruxolitinib for 6 h and subjected to immunoblot analysis. Abbreviations: S6K-PT, phospho-T389-p70S6 kinase; 4EBP1-nonP, non-phospho-T46-4EBP1. (C, D) PVTL-2 or HEL cells, as indicated, were treated for 6 h in ASF104 medium with 1 µM ruxolitinib or 1 µM GDC-0941, as indicated and analyzed. Abbreviations: S6RP-P, phospho-S240/244-S6RP; 4EBP1-S65P, phospho-S65-4EBP1; STAT5-PY, phospho-Y694-STAT5; PRAS40-P, phospho-T246-PRAS40; GSK3-P, phospho-S9-GSK3ß. (e) PVTL-1, PVTL-2, or HEL cells, as indicated, were treated for 6 h in ASF104 medium with or without 2 µM imatinib, as indicated, lysed, and immunoprecipitated with anti-c-Kit antibody. Immunoprecipitates (IP) and total cell lysates (TCL) were then subjected to immunoblot analyses with antibodies against indicated proteins. Abbreviations: PY, phosphotyrosine; STAT3-PY, phospho-Y705-STAT3.
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